Immunocore Holdings plc Foreign Currency Transaction Gain (Loss), before Tax
Immunocore Holdings plc (IMCR) reported Foreign Currency Transaction Gain (Loss), before Tax of -$1.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-06
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$1.11M.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $3.85M, a 24.97% increase year-over-year.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$1.46M.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $1.33M, a 66.36% decline year-over-year.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2025 was $2.21M.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2024 was -$3.45M.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2023 was -$13.18M, a 193.07% decline from fiscal 2022.
- Immunocore Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2022 was $14.16M, a 4798.62% increase from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.11M 10-Q · filed 2026-08-06 | $2.74M 10-Q · filed 2026-08-06 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $2.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.85M 10-Q · filed 2026-05-06 | $2.39M derived: sum of 2 quarters · filed 2026-05-06 | $3.72M derived: sum of 3 quarters · filed 2026-05-06 | $2.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$127.00K derived: sum of 2 quarters · filed 2026-02-25 | -$865.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.21M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.33M 10-Q · filed 2025-11-06 | $595.00K derived: sum of 2 quarters · filed 2026-08-06 | $3.67M 10-Q · filed 2025-11-06 | -$822.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$738.00K 10-Q · filed 2026-08-06 | $2.34M 10-Q · filed 2026-08-06 | -$2.15M derived: sum of 3 quarters · filed 2026-08-06 | $1.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.08M 10-Q · filed 2026-05-06 | -$1.42M derived: sum of 2 quarters · filed 2026-05-06 | $2.55M derived: sum of 3 quarters · filed 2026-05-06 | $2.04M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$534.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.04M derived: sum of 3 quarters · filed 2026-02-25 | -$3.45M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.96M 10-Q · filed 2025-11-06 | $3.46M derived: sum of 2 quarters · filed 2025-11-06 | $1.05M 10-Q · filed 2025-11-06 | -$11.48M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$508.00K 10-Q · filed 2025-08-07 | -$2.91M 10-Q · filed 2025-08-07 | -$15.44M derived: sum of 3 quarters · filed 2026-02-25 | -$4.20M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$2.41M 10-Q · filed 2025-05-07 | -$14.94M derived: sum of 2 quarters · filed 2026-02-25 | -$3.69M derived: sum of 3 quarters · filed 2026-02-25 | -$9.57M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$12.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.28M derived: sum of 2 quarters · filed 2026-02-25 | -$7.16M derived: sum of 3 quarters · filed 2026-02-25 | -$13.18M 10-K · filed 2026-02-25 |
| 2023-09-30 | $11.25M 10-Q · filed 2024-11-06 | $5.37M derived: sum of 2 quarters · filed 2024-11-06 | -$647.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$5.88M 10-Q · filed 2024-08-08 | -$11.89M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$6.01M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $14.16M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $289.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |